Antisense and RNAi Therapeutics Market Trends and Opportunities Analysis Report

Ongoing and planned human clinical trials in antisense and RNA interference (RNAi) have witnessed strides on the back of RNAi getting traction as a real therapeutic modality. A number of anti-sense based approaches that show promise for therapeutic applications have emerged over the past few two decades, driving the evolution of the in antisense and RNA interference (RNAi) market. Of all, RNAi therapeutics have attracted special attention, given the fact that they use oligonucleotides for targeting RNAs in various diseases that have significant worldwide mortality and public health burden. Rise in new approaches in antisense oligonucleotides (ASO) has also helped leverage the mechanism of these in the studying the underlying mechanism of cancer and neurodegeneration.

Get Sample Copy of this Report @

A growing number of trials have been conducted in recent years for use of ASO in amyotrophic lateral sclerosis and spinal muscular atrophy have opened new vistas in disease therapeutics Ongoing studies in RNA therapeutics in these diseases have enriched antisense and RNA interference (RNAi) market. More prominently, RNAi has been opening new avenues in  the management of genetic diseases. In contrast to protein, they are preferred due to high  specificity, remarkable potency, and reduced toxicity.

Growing Scope of RNA Medicine Set Tone for Innovation

The growing scope of RNA medicine is a key trend that will drive new opportunities for players in the in antisense and RNA interference (RNAi) market. Emerging siRNA-based therapeutic approaches are key to expanding avenues in the antisense and RNA interference (RNAi) market. However, technical limitations such as those of efficacy and off-target effects might restrain the prospective demand in antisense and RNA interference (RNAi) market.

Rise in research on chronic diseases where RNA therapeutics holds high clinical potential has expanded the horizon for players in the market. Over the years, siRNA based drugs have been extensively studied for cardiovascular diseases, renal cell carcinoma, and chronic Hepatitis B infection.

Check Table of Contents of this Report @

Author: Rohit Bhisey

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business.

Leave a Reply